Loading clinical trials...

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period

NCT00781937•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pressure) or dyslipidaemia (an abnormal amount of lipids in the blood). Trial has following trial periods: A 12-week run-in period (from week -12 to week 0) followed by a 56-week main trial period (weeks 0-56) and a 12-week follow-up period (weeks 56-68).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Body Mass Index (BMI) of either 30 kg/m\^2 or more or BMI of less than 30 kg/m\^2 to 27 kg/m\^2 with presence of co-morbidities
•Stable body weight during the previous 3 months (less than 5 kg self-reported weight change)
•Previously undergone dietary weight loss and was not able to maintain reduced weight

Exclusion Criteria

•Diagnosis of type 1 or type 2 diabetes
•Previous treatment with GLP-1 (glucagon-like peptide-1) receptor agonists (including liraglutide or exenatide), within the last 3 months
•Visit 1 thryoid stimulating hormone (TSH) outside of the range of 0.4-6.0 mIU/L
•History of chronic pancreatitis or idiopathic acute pancreatitis
•Obesity induced by other endocrinologic disorders (e.g., Cushing Syndrome)
•Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial
•Current participation in an organized diet reduction program (or within the last 3 months)
•Currently using or have used within three months before this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phenteremine, or metformin
•Previous surgical treatment for obesity (excluding liposuction if performed more than one year before trial entry)
•History of major depressive disorder or a PHQ-9 (Patient Health Questionnaire-9) score of more than 15 within the last 2 years or history of other severe psychiatric disorders or diagnosis of an eating disorder
+1 more criteria

Locations (37)

Novo Nordisk Investigational Site

Goodyear, Arizona, United States

Novo Nordisk Investigational Site

Peoria, Arizona, United States

Novo Nordisk Investigational Site

Huntington Beach, California, United States

Novo Nordisk Investigational Site

Montclair, California, United States

Novo Nordisk Investigational Site

Colorado Springs, Colorado, United States

Novo Nordisk Investigational Site

Hialeah, Florida, United States

Novo Nordisk Investigational Site

Pembroke Pines, Florida, United States

Novo Nordisk Investigational Site

Atlanta, Georgia, United States

Novo Nordisk Investigational Site

Meridian, Idaho, United States

Novo Nordisk Investigational Site

Louisville, Kentucky, United States

Key Dates

Start Date

October 30, 2008

Primary Completion Date

September 1, 2010

Completion Date

September 1, 2010

Last Updated

November 1, 2017

Enrollment

422

ACTUAL participants

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

liraglutide

DRUG

placebo

DRUG

Sponsors

Lead Sponsor

Novo Nordisk A/S

Related Studies

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 1, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions